Vibativ

DRUG2 trials

Sponsors

Cumberland Pharmaceuticals

Conditions

Complicated Skin and Skin Structure InfectionsGram Positive InfectionHospital Acquired Bacterial PneumoniaPregnancyVentilator Associated Bacterial Pneumonia

Unknown Phase

VIBATIV Pregnancy Registry

WithdrawnNCT01130324

Cumberland PharmaceuticalsPregnancy

Start: 2009-11-30End: 2020-10-31Updated: 2020-10-19

Telavancin Observational Use Registry (TOUR)

CompletedNCT02288234

Cumberland PharmaceuticalsComplicated Skin and Skin Structure Infections, Gram Positive Infection, Hospital Acquired Bacterial Pneumonia +1

Start: 2014-11-30End: 2017-10-31Updated: 2019-01-15

Related Papers

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™).

2021-05-264 citations

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

2020-09-018 citations

Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.

2015-09-0120 citations